JHS Svendgaard Laboratories Limited — Others, 13-11-2024: Statement of deviation(s) or variation(s) under Reg. 32

JHS Svendgaard Laboratories Limited has announced a board meeting to review the Statement of Deviation in the utilization of funds raised through a preferential issue for the quarter ended September 30, 2024. The company raised ₹29.99 crores, with ₹19.99 crores from equity shares and ₹9.99 crores from fully convertible warrants. Notably, there was no deviation in the use of these funds, affirming adherence to the original intended purposes, including setting up a new project in Jammu and Kashmir. This update may bolster investor confidence given the clear utilization track record, presenting a positive outlook for future operations.